Antisense approach for the treatment of cytomegalovirus infection

Bibliography

• MCAULLIFFE PF, HALL MJ, CASTRO-MALASPINA H, HEINE-MANN MH: Use of the ganciclovir implant for treating cytomegalovirus retinitis secondary to immunosup-pression after bone marrow transplantation. Am. J. Ophthalmol (1997) 123:702–703.
   PubMed Web of Science ®Google Scholar
• BRIGHT DC: Pharmacologic management of cytomega-@ lovirus retinitis: review of current and future therapeu-tic modalities. J. Am. Optom. Assoc. (1997) 68:11–30.
   PubMedGoogle Scholar
• RUBIN RH, COMM AB, TOLKOFF-RUBIN NE, RUSSELL PS, HIRSCH MS: Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation (1977) 24:458–464.
   PubMed Web of Science ®Google Scholar
• MARKER SC, HOWARD RJ, SIMMONS RL et al.: Cytomega-lovirus infection: a quantitative prospective study of 320 consecutive renal transplants. Surgery (1981) 89:660–671
   PubMed Web of Science ®Google Scholar
• ALFORD CA, BRITT WJ: Cytomegaloviruses. In: Virology Fields BN, Knipe DM (Eds), Raven Press, New York (1990):1981–2010.
   Google Scholar
• JACOBSON MA, MILLS J: Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann. Intern. Med. (1988) 108:585–594.
   PubMed Web of Science ®Google Scholar
• COLLABORATIVE DHPG TREATMENT STUDY GROUP: Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl) guanine in pa-tients with AIDS and other immunodeficiencies. New Engl. J. Med. (1986) 27:801–805.
   Google Scholar
• HENDERLY DE, FREEMAN WR, CAUSEY DM, RAO NA: Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology (1987) 94:425–434.
   PubMed Web of Science ®Google Scholar
• JABS DA, ENGER C, BARTLETT JG: Cytomegalovirus ret-initis and acquired immunodeficiency syndrome. Arch. Ophthalmol (1989) 107:75–85.
   PubMed Web of Science ®Google Scholar
• JACOBSON MA, DREW WL, FEINBERG J et al.: Foscarnet therapy for ganciclovir resistant cytomegalovirus ret-initis in patients with AIDS. J. Infect. Dis. (1991) 163:1348–1351.
   PubMed Web of Science ®Google Scholar
• PALESTINE AG, POLIS MA, DE SMET MD et al.: A random-ised, controlled trial of fosearnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann. Intern. Med. (1991) 115:665–673.
   Google Scholar
• HAFFEY ML, FIELD KA: Selective inhibition of cytomega-lovirus replication. In:Ant/14ra/ Chemotherapy Jeffries DJ, De Clercq E (Eds), John Wiley & Sons Ltd. (1995):83–126.
   Google Scholar
• IVES D: Cytomegalovirus infection. In: HIV Infection, aPrimary Care Manual. Ubman, Witzburg (Eds), (1996) 3 (24):363–381.
   Google Scholar
• Antisense Research and Applications. Crooke ST, Lebleu B(Eds), CRC, Boca Raton (1993).
   Google Scholar
• TEMSAMANI J, AGRAWAL S: Antisense oligonucleotides as antiviral agents. In: Advances in Antiviral Drug Design. DeClercq (Ed.), JAI Press, Inc. (1996) 2:1–39.
   Google Scholar
• Antisense Therapeutics. Agrawal S (Ed.), Humana, Totowa (1996).
   Google Scholar
• FIELD KA, GOODCHILD J: Antisense oligonucleotides: rational drug design for genetic pharmacology. Exp. Opin. Invest. Drugs (1995) 4:799–821.
   Google Scholar
• PRISBE EJ, MARTIN JC, MCGEE PC et al.: Synthesis and antiherpes virus activity of phosphate and phosphon-ate derivatives of 9-[(1,3-dihydroxy-2-propoxy)methyl] guanine. J. Med. Chem. (1986) 29:671–675.
   PubMed Web of Science ®Google Scholar
• FAULD D, HEE RC: Ganciclovir. Drugs (1990) 39:597–638.
   PubMed Web of Science ®Google Scholar
• LEVINSON ML, JACOBSON PA: Treatment and prophy-laxis of cytomegalovirus disease. Pharmacotherapy (1992) 12:300–318.
   PubMed Web of Science ®Google Scholar
• PAUL S, DUMMER, S: Topics in clinical pharmacology:ganciclovir. Am. J. Med. Sci. (1992) 304:272–277.
   PubMed Web of Science ®Google Scholar
• NEVINS TE, DUNN DL: Use of ganciclovir for cytomega-lovirus infection. J. Am. Soc. Nephrol (1992) 2:S270–S273.
   PubMed Web of Science ®Google Scholar
• SPECTOR SA, MCKINLEY GF, LALEZARI JP et al.: Oral ganciclovir for the prevention of cytomegalovirus dis-ease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. (1996) 334:1491–1497.
   Google Scholar
• CHRISP PL, CLISSOLD SP: Foscarnet. Drugs (1991) 41:104–129.
   PubMed Web of Science ®Google Scholar
• SNOECK R, SAKUMA T, DE CLERCQ E et al.: (S)-1-(3-Hy-droxy-2-phosphonylmethoxypropy0 cytosine, a po-tent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. (1988) 32:1839–1844.
   Google Scholar
• DE CASTRO LM, KERN ER, DE CLERCQ E et al.: Phos-phonylmethoxyalkyl purine and pyrimidine deriva-tives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. Antiviral Res. (1991) 16:104–114.
   Google Scholar
• STALS FS, DE CLERCQ E, BRUGGEMAN CA: Comparative activity of: (S)-1-(3-Hydroxy-2-phosphonyl-methoxypropyl) cytosine [IiPMPC] and 9-(1,3-dihy-droxy-2-propoxymethy0 guanine [DHPG] against rat cytomegalovirus infection in vitro and in vivo. Antimi-crob. Agents Chemother. (1991) 35:2262–2266.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: Therapeutic potential of cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e., herpes-, papova-, pox- and adenovirus) infections. Verh. K. Acad. Genneskd. Belg. (1996) 58:19–49.
   Google Scholar
• STINSKI MF: Cytomegalovirus and its replication. In: Virology Fields BN, Knipe DM (Eds), Raven Press, New York (1990):1959–1980.
   Google Scholar
• GIBSON W: Cytomegalovirus protein structure andfunction. In: Progress in Cytomegalovirus Research. Landini MP (Ed.), Elsevier, Amsterdam (1990:357–370.
   Google Scholar
• AZAD RF, DRIVER VB, TANAKA R, CROOKE RM, ANDER- SON KP: Antiviral activity of a phosphorothioate oli-gonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimi-crob. Agents Chemother. (1993) 37:1945–1954.
   PubMed Web of Science ®Google Scholar
• PART GS, FIELD KA, SMITH JA: Potent antiviral activity of •an antisense oligonucleotide complementary to theintron-exon boundary of human cytomegalovirus genes UL36 and UL37. Antimicrob. Agents Chemother. (1995) 39:1157–1161.
   PubMed Web of Science ®Google Scholar
• SMITH JA, PARI GS: Expression of human cytomega- lovirus UL36 and UL37 genes is required for viral DNA replication. J. Virol. (1995) 69:1925–1931.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, TEMSAMANI J, GALBRAITH W, TANG JY: Pharmacokincties of antisense oligonucleotides. Clin. Pharmacokinet. (1995) 28:7–16.
   PubMed Web of Science ®Google Scholar
• COHEN JS: Phosphorothioate oligodeoxynucleotides. In: Antisense Research and Applications. Crooke ST, Lebleu B (Eds), CRC, Boca Raton (1993):205–222.
   Google Scholar
• METELEV V, LISZIEWICZ J, AGRAWAL S: Study of antisense oligonucleotide phosphorothioates containing seg-ments of oligodeoxynucleotides and 2`-0-methyloli-goribonucleotides. Bioorg. Med. Chem. Lett. (1994) 24:2929–2934.
   Web of Science ®Google Scholar
• AGRAWAL S, JIANG Z, ZHAO Q et al.: Mixed-backboneoligonucleotides as second generation antisense oli-gonucleotides: in vitro and in vivo studies. Proc. Natl. Acad. Sci. USA (1997) 94:2620–2625.
   PubMed Web of Science ®Google Scholar
• LOKE SL, STEIN CA, ZHANG XH et al.: Characterisation of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. (1989) 86:3474–3478.
   PubMed Web of Science ®Google Scholar
• AKHTAR S, JULIANO RL: Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol. (1992) 2:139–144.
   PubMedGoogle Scholar
• ZHAO Q, MATSON S, HERRARA CJ et al.: Comparison of cellular binding and uptake of antisense phosphodi-ester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res. Dev. (1993) 3:53–66.
   PubMedGoogle Scholar
• TEMSAMANI J, KUBER TM, TANG JY, PADMAPRIYA A, AGRAWAL S: Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs. Antisense Res. Dev. (1994) 4:35–42.
   PubMedGoogle Scholar
• LEONNETI JP, LESERMAN LD: Target delivery of oligonu-cleotides. In: Antisense Research and Applications. Crooke ST, Lebleu B (Eds), CRC, Boca Raton (1993):493–504.
   Google Scholar
• ZON G, GEISER TG: Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions. Anti-Cancer Drug Design (1991) 6:539–568.
   PubMedGoogle Scholar
• PADMAPRIYA AA, TANG JY, AGRAWAL S: Large-scale synthesis, purification, and analysis of oligodeoxynu-cleotide phosphorothioates. Antisense Res. Dev. (1994) 4:185–199.
   PubMedGoogle Scholar
• ZAMECNIK PC, STEPHENSON ML: Inhibition of Roussarcoma virus replication and transformation by a specific oligodeoxynucleotide. Proc. Nad. Acad. Sc1 USA (1978) 75:280–285.
   PubMed Web of Science ®Google Scholar
• TEMSAMANI J, AGRAWAL S, PEDERSON T: Biotinylatedantisense methylphosphonate oligodeoxynucleotides. J. Biol. Chem. (1991) 266:468–472.
   PubMedGoogle Scholar
• ECKER DJ, VICKERS TA, BRUICE TW et al.: Pseudo-half-knot binding to RNA. Science (1992) 257:958–961.
   PubMed Web of Science ®Google Scholar
• STEPHENSON ML, ZAMECNIK PC: Inhibition of Roussarcoma viral RNA translation by a specific oligode-oxynucleotide. Proc. Natl. Acad. Sci. USA (1978) 75:285–290.
   PubMed Web of Science ®Google Scholar
• CROUCH RJ, DIRKSEN ML: Ribonucleases. In: Nucleases.Linn SM, Roberts RJ (Eds.), Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1985):211–241.
   Google Scholar
• PART GS, ANDERS DG: Eleven loci encoding trans-actingfactors are required for transient complementation of human cytomegalovirus oriLyt-dependent DNA replica-tion. J. Virol (1993) 67:6979–6988.
   PubMed Web of Science ®Google Scholar
• PART GS, KACIKA MA, ANDERS DG: Open reading frames UL44, IRSI/TRS1, and UL36-38 are required for transient complementation of human cytomegalovirus oriLyt-dependent DNA synthesis. J. Virol (1993) 67:2575–2582.
   PubMed Web of Science ®Google Scholar
• CHALLBERG MD: A method for identifying the viral genes required for herpesvirus DNA replication. Proc. Natl. Acad. Sci. USA (1986) 83:9094–9098.
   PubMed Web of Science ®Google Scholar
• MCVOY MA, ADLER SP: Human cytomegalovirus DNAreplicates after early circularisation by concatemer formation, and inversion occurs within the concate-mer. j Vim]. (1994) 68:1040–1051.
   Google Scholar
• MCVOY MA, ADLER SP: Analysis of human cytomega-lovirus (HCMV) DNA replicative intermediates: DNA forms not predicted by the rolling circle model. In: Progress in Cytomegalmdrus Research. Landini MP (Ed.), Elsevier, Amsterdam (199 0 :53–56.
   Google Scholar
• ANDERSON KP, FOX MC, BROWN-DRIVER V, MARTIN MJ, AZAD RF: Inhibition of human cytomegalovirus imme-diate-early gene expression by an antisense oligonu-cleotide complementary to immediate-early RNA. Antimicrob. Agents Chemother. (1996) 40:2004–2011.
   PubMed Web of Science ®Google Scholar
• HUTCHERSON SL, PALESTINE AG, CANTRILL HL et al.: Antisense oligonucleotide safety and efficacy for CMV retinitis in AIDS patients. 35th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA (1995):204.
   Google Scholar
• CROOKE ST: Progress in the development of antisense drugs. Exp. Opin. Invest. Drugs (1996) 5:1047–1052.
   Google Scholar
• ZHANG Z, SMITH JA, SMYTH AP et al.: Inhibition of human cytomegalovirus DNA replication with a phos-phorothioate cholesteryl-modified oligonucleotide is mediated by rapid cellular association and virus-facili-tated nuclear localisation. Antiviral Chem. Chemother. (1997) 8:255–264.
   Web of Science ®Google Scholar
• DVORCHIK BH, GRINDEL MJ, FERDINANDI ES: Retinal uptake, auto-radiography and metabolic profiling of GEM®132 in male Dutch belted rabbits and rhesus monkeys after a single intravitreal injection of 14C- or 355-GEM®132. Ant/sense 97: Targeting the Molecular Basis of Disease. Cambridge, MA. Abstract 21.
   Google Scholar
• GUINOT P, MARTIN R, BONVOISIN B et al.: First Phase I study of a new advanced chemistry systemic anti-CMV antisense compound (GEM®132) in healthy male vol-unteers. Fourth Conference on Retroviruses and Opportun-istic Infections. Washington DC (1997)309.
   Google Scholar